A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04171843 |
|
Recruitment Status :
Terminated
(Study was terminated due to lack of sufficient therapeutic effect)
First Posted : November 21, 2019
Last Update Posted : September 21, 2023
|
Sponsor:
Precision BioSciences, Inc.
Information provided by (Responsible Party):
Precision BioSciences, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 19, 2022 |
| Actual Study Completion Date : | October 19, 2022 |